Sermorelin
Category 1Also known as: Geref, GRF 1-29
Growth Hormone SecretagogueLast reviewed: April 28, 2026
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.
Mechanism of Action
Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.
Common Uses
- Growth hormone deficiency treatment
- Anti-aging protocols
- Improved sleep
- Body composition improvement
- Recovery enhancement
Known Risks
- Injection site reactions (redness, swelling)
- Headaches
- Flushing
- Dizziness
- Generally well-tolerated in clinical studies
Regulatory Status
Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
200–500 mcg
Frequency
Once daily before bed
Cycle Length
3–6 months (longer cycles than other GHS due to gentler action)
The most conservative GH secretagogue — good starting point for GH optimization. Inject before bed on empty stomach. Effects build gradually over weeks.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.